Top differential primary and secondary BAs somewhat reduced the proliferation, activation (CD69 expression), and cytotoxic pore formation (CD107a membrane localization) of CLL-suppressed CD8+ T-cells, yet CD8+ T-cell inflammatory cytokine (IFN-γ and TNF-α) production was unaffected by any BA treatment (Figure 4B,C). The gene discussed is LAMP1; the disease is B-cell chronic lymphocytic leukemia.